| Document |
Document Title |
|
WO/2009/082347A1 |
The invention provides compounds of formula (I) wherein R1,R3,L1,L2,G1,G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with pro...
|
|
WO/2009/081891A1 |
Disclosed is a compound represented by the general formula (I), which has a strong COMT inhibitory effect, or a pharmacologically acceptable salt thereof. Also disclosed are a pharmaceutical composition containing the compound or a pharm...
|
|
WO/2009/080725A1 |
The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; R1 is up to two subs...
|
|
WO/2009/080797A1 |
This invention relates generally to a solution processable norbornene monomer, poly(norbornene) homopolymer, and poly(norbornene) copolymer compounds containing a functionalized bis -oxadiazole side chain, and to an electron injecting/tr...
|
|
WO/2009/079593A1 |
The present invention is directed to piperidinyl and piperazinyl derivatives of formula (I) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compoun...
|
|
WO/2009/079597A1 |
The present invention is directed to piperidinyl and piperazinyl derivatives of formula (II) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compou...
|
|
WO/2009/075080A1 |
Disclosed is a fluoroalkylsulfide derivative having excellent pest control activity or a salt thereof. Also disclosed is a pest control agent characterized by containing such a fluoroalkylsulfide derivative or a salt thereof as an active...
|
|
WO/2009/074733A2 |
The invention relates to compounds of the formula (I) in which A is an angiotensine-converting enzyme inhibitor including at least one salifiable basic function, B is a compound including at least one acidic sailifiable function and at l...
|
|
WO/2009/071577A1 |
Oxadiazole derivatives of formula (I) where ring A is a bicyclic or tricyclic system. Claimed compounds are active on nicotinic acetylcholine receptors (nAChRs), and are useful to treat neurological, psychiatric, and gastrointestinal dis...
|
|
WO/2009/067797A1 |
Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these para...
|
|
WO/2009/067663A1 |
1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such a...
|
|
WO/2009/060278A1 |
The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof. This invention also relates to a method of using such compounds in the treatment of hyperproliferative di...
|
|
WO/2009/058552A1 |
The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with β- amyloid pept...
|
|
WO/2009/054923A2 |
The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,
4-oxadiazol-2-yl)phenyl]methyl} azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile
, and novel sa...
|
|
WO/2009/054423A1 |
[PROBLEMS] To provide a compound which is useful as a medicinal agent having an agonistic activity on a GPR40 receptor, particularly an insulin secretion promoter or a prophylactic and/or therapeutic agent for diabetes. [MEANS FOR SOLVIN...
|
|
WO/2009/049961A2 |
The present invention refers to new NO-donors aspirin derivatives, a process for their preparation and pharmaceutical compositions containing them.
|
|
WO/2009/051718A2 |
The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium se...
|
|
WO/2009/043890A1 |
The invention relates to compounds of formula (I): wherein R1, R2, Ra , Rb,Rc and W, have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
|
|
WO/2009/041972A1 |
Embodiments of the present invention provide novel antibactehals that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein...
|
|
WO/2009/040507A1 |
Compounds of formula (IA) or (IB) have antibacterial activity : wherein W is =C(H)- or =N-; R3 is a radical of formula -(Alk1)m-(Z1)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z...
|
|
WO/2009/034396A2 |
Methods for overcoming multiple herbicide resistance (MHR) in plants using inhibitors of GST suppression of Formula (I), novel chemical inhibitors of Formula (Ia), compositions comprising compounds of Formula (I), and uses and methods re...
|
|
WO/2009/023854A1 |
Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors. Formula (I):
|
|
WO/2009/008748A1 |
Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
|
|
WO/2009/004990A1 |
It is intended to provide a prostaglandin F2α receptor agonist (FP receptor agonist), which comprises a biphenyl derivative represented by the following general formula (I) (wherein m represents an integer of 0 to 2; n represents an int...
|
|
WO/2009/005076A1 |
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic nephropathy. [MEANS FOR SOLVING PROBLEMS] As a result of an intensive and extensive study on compounds having antagonistic activities on...
|
|
WO/2008/157407A2 |
Compounds of formula (I) hat are inhibitors of transcription factors of leukemia cell lines are provided. In addition, pharmaceutical compositions including the inhibiting compounds and methods for treating leukemia are also provided.
|
|
WO/2008/152149A1 |
The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1 -phosphate (S1 P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also direc...
|
|
WO/2008/135447A1 |
This invention relates to novel acetamide derivatives that are found to be potent modulators of ion channels, in particular potassium channels and chloride channels, and, as such, are valuable candidates for the treatment of diseases or ...
|
|
WO/2008/129129A1 |
Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein R is a heterocyclic or heterocyclic carbonyl moiety and R' is a group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted hetero...
|
|
WO/2008/130370A1 |
Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or pre...
|
|
WO/2008/129319A1 |
Sodium, magnesium, tert -butylammonium salt, tris( hydroxymethyl)methylammonium, triethanolammonium, diethanolammonium, ethanolammonium, methylethanolammonium, diethylammonium and nicotinamide salts of a compound of formula (I) are provi...
|
|
WO/2008/124878A1 |
The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them. A representative example of these compounds is formula (III).
|
|
WO/2008/123207A1 |
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic neuropathy. [MEANS FOR SOLVING PROBLEMS] Disclosed is an ornithine derivative having an EP4 receptor antagonistic activity. In the compo...
|
|
WO/2008/123349A1 |
Disclosed is an N-phenyl-N'-phenylsulfonylpiperazine derivative. Also disclosed is a method for efficiently producing an intermediate for the N-phenyl-N'-phenylsulfonylpiperazine derivative. Specifically disclosed is a method for produci...
|
|
WO/2008/122787A1 |
The present invention relates to compounds of general formula (I): wherein A, Y, X, n and B are as defined herein; and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever,...
|
|
WO/2008/119028A1 |
Alkenydiarylmethane compounds are described. Such compounds are a class of non-nucleoside inhibitors of HIV-I reverse transcriptase, which may also be used as part of a combination therapy to treat HIV infection. Compounds described here...
|
|
WO/2008/115259A2 |
This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of...
|
|
WO/2008/107501A1 |
The invention relates to a compound of general formula (I) for use in a pharmaceutical composition for treating infectious diseases caused by Helicobacter pylori. R1 and R2 are O, S or N, and can be identical or different; R3 is O or S; ...
|
|
WO/2008/107677A2 |
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X is an oxygen or sulphur atom A is CH(R6)-, -O- or NR7 or when A is NR7, then R1 and NR7 can together form a ring such that R1 and R7 are (CH2)n...
|
|
WO/2008/105607A1 |
A novel heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-r...
|
|
WO/2008/096760A1 |
Disclosed is a label which can label a molecule readily (i.e., which has a high labeling reaction rate) and can provide a high reaction yield. Also disclosed is a precursor for the production of the label. Specifically disclosed are: a h...
|
|
WO/2008/080511A1 |
The present invention relates to heteroarylcyclopropanecarboxamides of the formula (I), in which Het, X, Ra, Rb, Rc, Rd, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxid...
|
|
WO2008039431B1 |
The present invention relates to crystalline forms of 3- [5- (2 -fluorophenyl) - [l,2,4]oxadiazol-3-yl] -benzoic acid (formula (I)), pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the cry...
|
|
WO/2008/079836A2 |
The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2,...
|
|
WO/2008/077507A1 |
The present invention relates to heteroaryl-substituted carboxamides of the formula (I) in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) syntha...
|
|
WO/2008/064320A2 |
Hydrindane analogs of formula (IA) and (IB) that have agonist activity at one or more of the SlP receptors are provided. The ' compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.
|
|
WO/2008/064315A1 |
Tetralin analogs that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.
|
|
WO/2008/059128A1 |
The present invention relates to new phenylic derivatives, wherein these products exhibit a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. They are of particular interest for treating patho...
|
|
WO/2008/058178A1 |
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions containing the same and methods of use thereof related to the treatment of cancer and other diseases. Formula (I).
|
|
WO/2008/057775A2 |
A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with th...
|
